{"filings":[{"id":1500918,"accession_number":"0001079973-26-000934","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-07-07T21:00:11+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"TOI secures $75M OrbiMed term loan, repays $86M Deerfield convertible note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$75M term loan from OrbiMed, matures 2031, interest at SOFR+5.75% (floor 3%).","Repaid $86M Deerfield 4% senior secured convertible note using loan and ~$11M cash.","Issued warrants for 10,025,535 shares at $8.567 to Deerfield as part of repayment.","No new equity raised; transaction improves liquidity and extends debt maturities.","Covenant requires minimum net revenue of $700M for trailing 12 months starting Dec 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1139276,"accession_number":"0001553350-26-000093","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-06-18T20:30:18+00:00","items":["5.07"],"status":"ready","headline":"TOI stockholders elect all eight director nominees, ratify auditor, approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected eight directors: Brad Hively, Karen Johnson, Mohit Kaushal, Anne McGeorge, Mark Pacala, Mark Stolper, Kimberly Tzoumakas, Daniel Virnich.","Ratified BDO USA, P.C. as independent auditor for FY 2026 with 75,098,890 votes for, 37,257 against.","Say-on-pay approved with 25,280,934 for, 282,655 against, 12,126 abstain.","Advisory vote on executive compensation frequency: annual preferred with 24,918,766 votes (1-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":610365,"accession_number":"0001079973-26-000721","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-05-22T20:30:17+00:00","items":["1.05","7.01","9.01"],"status":"ready","headline":"Oncology Institute patient data accessed in Vendor cybersecurity incident; operations sustained","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["On May 20, 2026, Kroll notified TOI that its Vendor detected unauthorized access to TOI patient data systems.","Incident previously disclosed voluntarily in November 2025; now confirmed patient information compromised.","TOI states operations continued in all material respects since detection; offering credit monitoring to affected patients.","Company believes incident also affected other healthcare providers; reserving rights against third parties.","Evaluation ongoing; TOI currently believes no material impact on operations, financial condition, or quality of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95532,"accession_number":"0001079973-26-000611","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.","Adjusted EBITDA loss $2.4M improved from $5.1M loss; EPS $(0.02) vs $(0.21).","Specialty Pharmacy revenue up 78% YoY; record Part D fills.","Medicare Advantage lives to reach 200,000 in Florida effective July 1, 2026.","CMS Enhancing Oncology Model saved ~$2M in period 3; full-year guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":147441000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108675,"accession_number":"0001079973-26-000304","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncology Institute furnishes investor presentation; no material financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation provided for investor meetings; no earnings or guidance changes.","No specific financial figures or material events included in the filing.","Filing is a routine Regulation FD disclosure without new operational data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108674,"accession_number":"0001079973-26-000291","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).","Net loss narrowed to $7.5M from $13.2M; adj EBITDA improved to $147K from -$7.8M.","FY2025 revenue $502.7M (+27.8%); net loss $60.6M vs $64.7M; adj EBITDA -$12.4M vs -$35.7M.","Added 9 new capitated contracts in CA, FL, NV covering ~260K lives; expanded Elevance, Humana, CarePlus partnerships.","Cash from operations positive $3.2M in Q4; cash balance $33.6M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108673,"accession_number":"0001553350-26-000007","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"The Oncology Institute appoints Kim Tzoumakas to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Kim Tzoumakas, CEO of VytlOne National Pharmacy Services, to board effective Feb. 23, 2026.","Ms. Tzoumakas previously led 21st Century Oncology through a turnaround and strategic sale; serves on multiple healthcare boards.","She will receive $75k annual cash retainer paid quarterly plus restricted stock units for board service.","She was not initially assigned to any board committees; term expires at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108672,"accession_number":"0001079973-26-000068","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI reaffirms 2025 guidance, provides 2026 outlook: rev $630M-$650M, first full yr positive Adj EBITDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 revenue guidance $630M-$650M, ~28% growth from 2025 midpoint.","Capitation revenue ~$150M in 2026, driven by delegated contract expansion in Florida.","2026 Adjusted EBITDA guidance $0M-$9M, first full year of positive Adj EBITDA as public company.","Expects profitability from newly onboarded delegated contracts to build progressively during 2026, with fuller realization in 2027.","Growth driven by Dispensary volumes, organic growth, and new contract wins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108671,"accession_number":"0001079973-26-000051","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TOI appoints Mark Stolper to Board as Audit Committee Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark D. Stolper appointed to Board effective Jan 2, 2026; fills a vacancy.","Stolper is CFO of RadNet (RDNT) with prior oncology board experience.","Appointed Audit Committee Chairman and designated financial expert.","Will receive $75,000 annual retainer and future RSU grant for board service.","Term expires at next annual meeting; expected to be nominated for re-election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125122,"accession_number":"0001553350-25-000168","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Board member Gabe Ling resigns from The Oncology Institute board effective Dec 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gabriel Ling resigned from the Board of Directors, effective December 1, 2025, with no disagreement with the company.","Chairman Anne McGeorge thanked Ling for his service during TOI's early years as a public company.","Formal search initiated for new independent directors with healthcare, clinical, and value-based care expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125121,"accession_number":"0001079973-25-001724","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncology Institute provides investor presentation with no specific new financial disclosures","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation furnished under Regulation FD on November 14, 2025.","Presentation content not disclosed in filing; exhibit text appears corrupted or incomplete.","No accompanying earnings release, guidance change, or material event noted.","Company common stock (TOI) and warrants (TOIIW) listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125120,"accession_number":"0001079973-25-001707","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q3 revenue $136.6M (+37% YoY); adjusted loss narrows, raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $136.6M (+36.7% YoY); gross profit $18.9M (+31.7%); net loss $(16.5)M vs $(16.1)M.","Adjusted EBITDA improved to $(3.5)M from $(8.2)M; diluted EPS $(0.14) vs $(0.18) loss per share.","Retail pharmacy revenue $75.9M, set fill records, contributed $12.8M gross profit.","Fee-for-service revenue grew 13% YoY on organic growth in Florida and Oregon.","Full year 2025 guidance raised (specific figures not disclosed in filed excerpt)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":360772000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125119,"accession_number":"0001079973-25-001666","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncology Institute discloses cyber incident impacting fee-for-service collections","summary_kind":"llm","event_type":"cyber","confidence":"medium","bullets":["Cybersecurity incident at IT software provider may cause brief immaterial delay in fee-for-service collections.","No evidence of patient personal information compromise to date; investigation ongoing.","Company collaborating with provider to restore normal billing operations quickly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141831,"accession_number":"0001079973-25-001264","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q2 revenue $119.8M (+21.5% YoY); net loss $17.0M; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue of $119.8M, up 21.5% YoY from $98.6M; gross profit $17.5M, up 34.4%.","Net loss $17.0M vs $15.5M; diluted EPS $(0.15) vs $(0.17); Adjusted EBITDA $(4.1)M vs $(8.7)M.","Pharmacy revenue $62.6M with >$11M gross profit; over 40% YoY growth.","Expanding capitated partnership with Elevance into two new Florida counties (more than double lives) and with Silver Summit in Nevada.","Reaffirms full-year 2025 guidance; expects revenue at high end of range and positive Adjusted EBITDA by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":224208000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141830,"accession_number":"0001079973-25-001263","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Richard Barasch retires as Chairman of The Oncology Institute; Anne McGeorge appointed as new Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Barasch retired as Chairman effective Aug 12, 2025; no disagreement with company.","Anne McGeorge appointed as new Chairman; previously chaired Audit Committee since 2021.","McGeorge brings 35+ years healthcare finance experience; former Grant Thornton managing partner.","McGeorge also serves on boards of Dianthus Therapeutics (DNTH), Nimbus, and CitiusTech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159754,"accession_number":"0001079973-25-000905","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oncology Institute explores potential PIPE financing as disclosed in investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["The company is considering a private placement (PIPE) of securities according to the investor presentation cover.","No terms, size, or pricing of the potential PIPE have been disclosed in the filed excerpt.","The presentation is intended for meetings with prospective investors; no definitive agreement announced.","The company's common stock (TOI) and warrants (TOIIW) are listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159753,"accession_number":"0001079973-25-000800","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q1 revenue $104.4M (+10.3% YoY); net loss $19.6M vs $19.9M; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $104.4M, up 10.3% YoY from $94.7M; gross profit $17.2M, up 44.1%.","Net loss $19.6M ($0.21/share) vs $19.9M ($0.22) prior year; Adjusted EBITDA -$5.1M vs -$10.9M.","Pharmacy & Dispensary segment revenue $49.3M, gross profit >$9M, grew >20% YoY; FFS growth 9% QoQ.","Added >100,000 capitated lives in Q1; new contracts in FL, NV, CA; fully-delegated agreement started March 1 in FL.","Closed $16.5M private placement; exchanged $4.1M convertible notes for preferred stock & warrants; cash $39.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":104406000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159752,"accession_number":"0001079973-25-000774","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TOI shareholders approve reverse stock split up to 1:40; re-elect all 8 directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio between 1:5 and 1:40, board discretion within one year.","All eight director nominees elected; Richard Barasch received 39.2M votes for, 654k withheld.","Ratification of BDO USA as auditor for FY2025 approved with 61.2M for, 682k against.","Turnout of 61.9M shares representing 81.7% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159751,"accession_number":"0001079973-25-000764","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"The Oncology Institute COO Jeremy Castle resigns effective May 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy Castle provided notice of resignation as COO, effective May 30, 2025.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No successor or interim arrangement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159750,"accession_number":"0001079973-25-000610","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncology Institute regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Apr 9, 2025 that closing bid was $1.00+ for 12 consecutive days through Apr 8.","Had been non-compliant since June 2024; granted extension to June 16, 2025 before cure.","Compliance removes immediate delisting risk for common (TOI) and warrants (TOIIW)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178129,"accession_number":"0001079973-25-000486","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"The Oncology Institute closes ~$16.4M private placement and $4.1M note exchange","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 12.0M shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.","Exchange of $4.1M Deerfield convertible notes for Series A preferred stock (convertible into 3.7M shares) and warrants for 1.9M shares.","Company to file resale registration statement within 45 days; registration rights agreement includes liquidated damages for delays.","Total proceeds from private placement up to ~$16.4M; closing occurred March 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178128,"accession_number":"0001079973-25-000460","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"The Oncology Institute raises $16.5M via private placement and exchanges $4.1M notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$16.5M from issuing 12.0M common shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.","Deerfield exchanges ~$4.1M senior secured convertible notes for 37,233 preferred shares (convertible into 3.7M common) and warrants for 1.9M shares.","Common warrants exercisable at $1.1980/share for 5 years; pre-funded warrants at $0.0001/share.","Proceeds to support organic growth and working capital; closing expected March 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178127,"accession_number":"0001079973-25-000450","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"The Oncology Institute exploring PIPE financing; investor presentation filed March 24","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Filing on March 24, 2025 discloses investor presentation dated February 2025 for a potential PIPE financing.","No specific offering size, price, or use of proceeds were included in the presentation.","Company common stock (TOI) and warrants (TOIIW) trade on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178126,"accession_number":"0001079973-25-000446","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.","Positive Q4 operating cash flow of $4.2M; SG&A down 12% YoY.","Added six new value-based contracts in H2 2024 covering over 250k lives; dispensary revenue at record.","2025 guidance: revenue $420-$450M, adjusted EBITDA loss $19-$24M, improved free cash flow.","New drug-supplier agreement expected to improve discounts and cost positioning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178125,"accession_number":"0001079973-25-000324","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"TOI amends Deerfield credit agreement, removes $40M cash covenant, pays down $20M notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Deerfield waived restrictions on equity issuance and removed the $40M minimum cash covenant.","TOI made a ~$20M partial prepayment on senior secured convertible notes plus accrued interest.","Year-to-date TOI signed three new capitation agreements adding ~80,000 lives across CA, NV, FL.","Florida value-based lives exceed 200,000, with over 50,000 under Medicare Advantage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194795,"accession_number":"0001079973-24-001742","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Nasdaq grants TOI additional 180 days to meet $1 minimum bid price through June 16, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Second Nasdaq Bid Price Letter on Dec 19, 2024 granting extension to June 16, 2025.","Company must regain compliance with minimum $1.00 bid price by end of Second Compliance Period.","May consider a reverse stock split to cure deficiency; split must be completed 10 business days before deadline.","If compliance not met, Nasdaq will issue delisting notice; Company may appeal to Nasdaq Hearings Panel.","No immediate effect on listing or trading of common stock (TOI) or warrants (TOIIW)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194794,"accession_number":"0001799191-24-000028","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q3 revenue up 22% to $99.9M; net loss narrows to $16.1M, adjusted EBITDA -$8.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $99.9M (+21.8% YoY), driven by dispensary revenue surge of 79.9%.","Gross profit $14.4M (-10.1% YoY); SG&A reduced 6% to $26.6M.","Net loss $16.1M ($0.18 EPS) vs $17.4M loss in Q3 2023.","Adjusted EBITDA -$8.2M vs -$5.3M in prior year period.","Board completed strategic review; elected to continue current plan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":293145000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194793,"accession_number":"0001079973-24-001491","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Maeve O'Meara resigns effective Jan 1, 2025; Gabriel Ling to become independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maeve O'Meara notified board of her resignation as director for personal reasons, effective January 1, 2025.","Resignation is not the result of any disagreement with the company, board, or operations.","Board determined that existing director Gabriel Ling will qualify as independent as of the Effective Date.","After the departure, a majority of independent directors will remain on the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211088,"accession_number":"0001553350-24-000088","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TOI CFO Mihir Shah resigns; Rob Carter promoted to CFO effective Oct 14","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Mihir Shah resigns effective October 14, 2024, to pursue other opportunities; departure not related to operations or accounting policies.","Rob Carter, SVP of Finance since December 2021, promoted to CFO effective October 14, 2024; will serve as principal financial and accounting officer.","Carter brings over a decade of healthcare finance leadership, including roles at Hoag Health System, Kaiser Permanente, SCAN Health Plan, and McKesson.","Carter's initial base salary is $375,000 with a 40% target bonus; equity award to be granted on next regular quarterly grant date.","Shah will assist transition as an advisor under a consulting arrangement at an agreed hourly rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211087,"accession_number":"0001799191-24-000020","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).","Gross profit $13M (-13.9%); gross margin 13.2% vs 18.8%; adjusted EBITDA ($8.7M) vs ($6.9M).","Dispensary segment revenue up 76% YoY; 10 capitation contracts signed in 2024 so far.","Company exploring strategic alternatives to maximize shareholder value.","Cash $46.4M; full year 2024 guidance updated, expecting H2 improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":193244000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229599,"accession_number":"0001079973-24-000949","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"The Oncology Institute receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on June 20, 2024 for non-compliance with minimum bid price rule 5550(a)(2).","Common stock bid price below $1.00 per share for 30 consecutive business days.","180-day compliance period ends December 17, 2024; may get additional 180 days if eligible.","To regain compliance, bid price must close at $1.00+ for 10 consecutive business days.","Company will consider options including a reverse stock split, subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229598,"accession_number":"0001079973-24-000876","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve issuance of up to 20.46M shares in Deerfield convertible notes and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with strong support; broker non-votes of ~12.2M shares.","Ratification of BDO USA as independent auditor approved: 60.8M for, 192k against, 50k abstain.","Proposal 3 approved: allows issuance of up to 20,459,040 shares upon conversion of Deerfield convertible notes and exercise of warrants.","Turnout: 61.08M shares voted (82.06% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229597,"accession_number":"0001628280-24-023189","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncology Institute Q1 revenue up 24% to $95M; net loss narrows to $19.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $95M (+24.2% YoY); net loss $19.9M vs $30.0M loss in prior year.","Gross profit $12M (-15.1% YoY); gross margin 12.6% vs 18.5% a year ago.","Adjusted EBITDA loss of $10.9M vs $7.4M loss in prior year quarter.","Signed 7 new value-based contracts; reaffirmed full-year 2024 guidance.","Ended Q1 with 73 clinics, 126 providers; scripts dispensed up 70% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":94666000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229596,"accession_number":"0001628280-24-014573","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Oncology Institute issues FY2023 results slide presentation; no specific figures in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Presentation covers financial results for Q4 and full year ended Dec 31, 2023.","Company also provided business updates and guidance for the year ending Dec 31, 2023.","No quantitative data (revenue, EPS, etc.) appears in the provided excerpt of Exhibit 99.1.","Investors should review the full slide deck for actual performance metrics.","Filing date April 3, 2024; tickers TOI and TOIIW."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":94666000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248127,"accession_number":"0001628280-24-013295","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI reports Q4 revenue $86M (+20.1% YoY), net loss widens to $18.8M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2023 revenue $86M (+20.1% YoY); gross profit $14M (-8.0% YoY).","Net loss $18.8M (vs $11.0M loss in Q4 2022); diluted EPS -$0.21.","Adjusted EBITDA -$6.3M (vs -$4.6M in prior year quarter).","Operational: remediated material weakness, signed full-risk contract in South Florida, launched CA pharmacy with 1,300 specialty fills.","Ended 2023 with 69 clinics, 119 providers; cash $83M. 2024 outlook mentioned but not detailed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265588,"accession_number":"0001628280-23-037893","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI reports Q3 revenue $82M (+26% YoY), net loss widens to $17.4M from $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $82M (+26% YoY); gross profit $16M (+23% YoY); gross margin 19.5% (down from 20.0%).","Net loss $17.4M ($0.19 diluted loss) vs $2.7M loss ($0.03 loss) prior year; Adjusted EBITDA loss $(5.3)M vs $(6.7)M.","Cash and investments $87.4M as of Sept 30, 2023.","Opened 70th clinic, added 5 physicians (total 112); signed full-risk capitated contract in South Florida effective Jan 1, 2024.","Reaffirmed full year 2023 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":238451000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282794,"accession_number":"0001799191-23-000048","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncology Institute regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 15, 2023 confirming compliance with Listing Rule 550(a)(2).","Common stock closing bid price was $1.00 or more for 11 consecutive business days through Sept 14.","Company had been non-compliant since April 25, 2023; original deadline was Oct 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282793,"accession_number":"0001799191-23-000044","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"The Oncology Institute appoints Jeremy Castle as COO with $375K base salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeremy N. Castle appointed COO effective September 5, 2023, replacing Matthew Miller, MD who departed June 16, 2023.","Castle previously served as VP of Operations at OneOncology (Jan 2022-Aug 2023); over 15 years in healthcare operations.","Base salary $375,000; target annual bonus 40% of base; $50,000 signing/relocation bonus.","Employment agreement has three-year initial term; severance of three months salary/COBRA if terminated without cause or for good reason.","No family relationships with directors/officers; no related party transactions required to be disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282792,"accession_number":"0001799191-23-000042","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ravi Sarin resigns from The Oncology Institute board; no disagreement cited","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ravi Sarin resigned from the Board on August 31, 2023, effective immediately.","Resignation not related to any disagreement with the Company on operations, policies, or practices.","Sarin served on Audit, Compensation, and Compliance Committees; replacements to be considered.","Board size reduced to eight directors following Mr. Sarin's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282791,"accession_number":"0001799191-23-000040","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncology Institute authorizes up to 2M share repurchase at ≤$1.00; Deerfield consents","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repurchase of up to 2M shares of common stock at price not exceeding $1.00 per share.","Limited Consent with Deerfield permits repurchases on or before Sep 16, 2023 under same price cap.","Repurchased shares will be returned to authorized but unissued status.","Company not obligated to repurchase any shares; timing subject to market conditions.","Limited Consent also grants one-time waiver of certain notice requirements under Facility Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282790,"accession_number":"0001799191-23-000037","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Oncology Institute releases Q2 2023 results and 2023 guidance; no specific figures in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company furnished slide presentation with Q2 and H1 2023 financial results on August 10, 2023.","Management provided updated business guidance for the year ending December 31, 2023.","No revenue, EPS, or other numeric details are extractable from the available filing exhibits.","Tickers: TOI (common stock) and TOIIW (warrants)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":156416000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282789,"accession_number":"0001799191-23-000029","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TOI Q2 revenue up 32% to $80M, net loss widens to $16.9M, reaffirms FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $80M (+32% YoY); gross profit $15M (+36%); gross margin 18.8% vs 18.3%.","Net loss of $16.9M vs $5.5M loss in prior year; EPS $(0.19) vs $(0.06).","Adjusted EBITDA $(6.9)M, flat YoY; cash & investments $98M as of June 30, 2023.","Acquired Southland Radiation Oncology Network; patient visits up 14%, oral drugs dispensed up 38% YoY.","Reaffirmed full-year 2023 guidance; management cites strong topline growth and momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":156416000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302124,"accession_number":"0001799191-23-000027","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"The Oncology Institute shareholders elect all nine directors, ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["64,996,623 shares voted (~86.4% of outstanding) at June 15 annual meeting.","All nine director nominees elected with majority support; three nominees had ~13M votes withheld.","Ratification of BDO USA as independent auditor for FY 2023 passed with 64.3M for, 444k against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302123,"accession_number":"0001104659-23-071385","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncology Institute authorizes up to 5M share buyback at ≤$0.75; obtains lender consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repurchase of up to 5M shares of common stock at price not exceeding $0.75 per share.","Company entered Limited Consent with Deerfield to permit repurchases on or before June 16, 2023, at same price cap.","Repurchases may be made in open market or negotiated purchases; no obligation to repurchase any shares.","Limited Consent also waives certain notice requirements under the Facility Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302118,"accession_number":"0001799191-23-000020","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K/A","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.","Daniel Virnich, current President, appointed CEO effective June 30, 2023.","Hively receives salary continuation, COBRA premiums for 12 months, and 50% of 2023 annual bonus at Board discretion.","All unvested restricted stock units vest through June 30, 2024 per existing vesting schedules.","Transition was not the result of any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302122,"accession_number":"0001799191-23-000012","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Oncology Institute CEO Brad Hively steps down, President Daniel Virnich promoted to CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Hively resigns as CEO effective June 30, 2023; will become Vice Chairman of the Board.","Daniel Virnich, current President, appointed CEO effective June 30, 2023.","Hively's resignation not due to any disagreement; severance includes salary continuation, 50% of 2023 bonus, and RSU vesting through June 2024.","Virnich joined TOI in 2020 as COO, promoted to President; previously at DaVita and TeamHealth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302121,"accession_number":"0001799191-23-000006","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"COO Matthew Miller to depart June 16, 2023; duties assumed by President Virnich","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Matthew Miller terminated as COO effective June 16, 2023; severance includes 3 months base salary and healthcare.","Option exercise period extended to May 18, 2024, contingent on signing a general release of claims.","No replacement will be hired; President Dr. Daniel Virnich will absorb COO responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302120,"accession_number":"0001628280-23-017224","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncology Institute Q1 revenue $76M (+38% YoY) but net loss $30M, EBITDA loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $76M, up 38.1% YoY; gross profit $14M (18.5% margin, down from 22.3%).","Net loss of $30M ($0.33 diluted loss) vs net income of $19.3M ($0.22 EPS) in Q1 2022.","Adjusted EBITDA loss of $7.9M vs loss of $5.2M in prior year; cash of $114M.","Patient visits up 17% YoY; oral drugs dispensed up 34% YoY.","New value-based contracts in CA and TX; Florida gainshare shows >50% referral capture and >30% cost savings; Q3 guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":76192000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302119,"accession_number":"0001628280-23-013333","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Oncology Institute receives Nasdaq delisting warning over bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified TOI on Apr 25, 2023 of non-compliance with minimum bid price rule (5450(a)(2)).","Company has 180 calendar days, until Oct 23, 2023, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by Oct 23, may qualify for an additional 180-day period if meeting other listing standards.","Company may seek stockholder approval for a reverse stock split to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321799,"accession_number":"0001628280-23-009312","cik":1799191,"company_name":"Oncology Institute, Inc.","ticker":"TOI","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"The Oncology Institute issues FY2022 results and 2023 guidance; specific numbers not available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Slide presentation furnished as Exhibit 99.1 includes financial results for Q4 and FY2022.","Presentation also provides business update and guidance for the year ending December 31, 2023.","Exact revenue, EPS, or other financial figures are not disclosed in the provided filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":460921336.7276689,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-27T23:59:59+00:00|321799"}